Gyre Therapeutics (GYRE) AI Stock Analysis

• Market Cap: $683.93M
• Dividend Yield: N/A
• Average Volume (3M): 79.30K
• Price to Earnings (P/E): 474.2
• Beta (1Y): 1.20
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 579
• Sector: Healthcare
• Sector Strength: 50
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 96,313,156
• 10 Day Avg. Volume: 84,161
• 30 Day Avg. Volume: 79,297
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 7.23
• Enterprise Value/Gross Profit: 7.54
• Enterprise Value/Ebitda: 66.62
• 1Y Price Target: $22.10
• Price Target Upside: 192.72% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 58 Neutral
• Price Target: $8.50 ▲(12.58% Upside)

Gyre Therapeutics' overall stock score reflects a stable financial performance with strong gross margins but challenges in profitability and cash flow. Technical indicators suggest a bearish trend, and the stock appears overvalued based on its high P/E ratio. Positive corporate events, including leadership changes and successful trial results, provide a boost to the outlook.

Gyre Therapeutics Business Overview & Revenue Model

Company Description

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

How the Company Makes Money

Gyre Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company's revenue model includes funding from government grants, partnerships with larger pharmaceutical firms, and potential royalties from successful product sales. Key revenue streams involve milestone payments from collaborations that focus on advancing drug candidates through clinical trials, licensing agreements for proprietary technologies, and eventually, sales of approved therapies. Significant partnerships with research institutions and pharmaceutical companies also contribute to Gyre's financial stability by providing access to additional resources and expertise.

Gyre Therapeutics Financial Statement Overview

Summary

Gyre Therapeutics demonstrates strong gross profit margins and a stable balance sheet with low leverage. However, challenges exist in maintaining net profitability and generating positive free cash flow. Improvements in revenue growth and operating cash flow are noted, but the decline in return on equity and negative free cash flow highlight areas for improvement.

Income Statement

Gyre Therapeutics shows a strong gross profit margin of 95.9% in TTM, indicating efficient cost management. However, the net profit margin has decreased from 11.4% in 2024 to 7.9% in TTM, reflecting reduced profitability. Revenue growth is positive at 1.5% in TTM, but the company experienced a revenue decline in 2024. Overall, the income statement reflects solid gross margins but challenges in maintaining net profitability.

Balance Sheet

The company's debt-to-equity ratio is low at 0.015 in TTM, indicating low leverage and financial stability. Return on equity has decreased from 19.1% in 2024 to 11.2% in TTM, suggesting a decline in efficiency in generating returns for shareholders. The equity ratio is strong, highlighting a solid capital structure. Overall, the balance sheet is stable with low debt levels, but there is room for improvement in return on equity.

Cash Flow

Operating cash flow has improved to $927,000 in TTM from negative figures in 2024, but free cash flow remains negative, indicating cash flow challenges. The free cash flow to net income ratio is negative, reflecting inefficiencies in converting net income to cash. The cash flow statement shows improvement in operating cash flow but ongoing struggles with free cash flow generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	102.19M	105.76M	113.45M	102.29M	7.34M	20.95M
Gross Profit	98.01M	101.87M	108.81M	97.50M	-42.00K	11.79M
EBITDA	11.10M	17.82M	20.33M	10.33M	-87.60M	-57.37M
Net Income	8.04M	12.09M	-92.93M	2.30M	-87.93M	-55.54M
Balance Sheet
Total Assets	152.65M	125.41M	116.54M	84.75M	55.66M	94.85M
Cash, Cash Equivalents and Short-Term Investments	36.49M	26.67M	33.51M	25.18M	46.85M	79.35M
Total Debt	1.39M	1.60M	409.00K	613.00K	2.38M	1.64M
Total Liabilities	23.20M	27.00M	38.06M	12.54M	14.57M	18.78M
Stockholders Equity	92.03M	63.32M	-15.83M	42.52M	41.09M	76.07M
Cash Flow
Free Cash Flow	-79.00K	-5.96M	17.31M	-38.09M	-84.59M	-55.31M
Operating Cash Flow	927.00K	-3.64M	25.89M	-33.10M	-83.75M	-55.05M
Investing Cash Flow	-5.47M	-19.88M	-19.76M	55.43M	48.19M	9.66M
Financing Cash Flow	24.98M	2.10M	2.50M	-45.01M	49.55M	60.38M

Gyre Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.55
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GYRE, the sentiment is Positive. The current price of 7.55 is above the 20-day moving average (MA) of 7.47, below the 50-day MA of 7.58, and below the 200-day MA of 9.89, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 58.07 is Neutral, neither overbought nor oversold. The STOCH value of 71.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GYRE.

Gyre Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥352.94B	11.56	-1.45%	2.37%	9.60%	-12.34%
GYRE	58 Neutral	$683.93M	474.23	5.47%	―	―	―
XERS	55 Neutral	$1.19B	―	222.83%	―	35.62%	49.58%
ABCL	54 Neutral	$1.28B	―	-15.64%	―	-0.54%	-6.28%
NTLA	53 Neutral	$1.10B	―	-56.95%	―	14.99%	14.42%
NRIX	43 Neutral	$752.26M	―	-50.67%	―	41.86%	10.48%
PHVS	42 Neutral	$1.49B	―	-63.96%	―	―	-36.92%

Gyre Therapeutics Corporate Events

Gyre Therapeutics Appoints Dan Weng to Board

On August 18, 2025, Gyre Therapeutics appointed Dan Weng, M.D., as a Class II director to its Board of Directors. Dr. Weng, who has extensive experience in managing global clinical trials and has held leadership roles in various contract research organizations, is expected to bring strategic insight and regulatory expertise to Gyre as it expands its commercial reach and advances its multinational pipeline.

Gyre Therapeutics Appoints Ping Zhang as Interim CEO

On August 5, 2025, Gyre Therapeutics appointed Ping Zhang as Interim CEO following the resignation of Dr. Han Ying, who transitioned to a scientific leadership role. The company reported a net income of $1.6 million for Q2 2025 and reaffirmed its full-year revenue guidance. Gyre is progressing with its pipeline, including a pivotal Phase 3 trial of Hydronidone for CHB-associated liver fibrosis and the launch of Etorel in the PRC. The leadership change is expected to strengthen Gyre’s global expansion and accelerate its delivery of transformative therapies.

Gyre Therapeutics Holds 2025 Annual Stockholders Meeting

On June 4, 2025, Gyre Therapeutics, Inc. conducted its 2025 Annual Meeting of Stockholders, where all director nominees were elected and other proposals were approved. The meeting included the election of Class I directors to serve until the 2028 Annual Meeting, approval of executive compensation on a non-binding basis, and ratification of Grant Thornton Zhitong Certified Public Accountants LLP as the independent auditor for 2025.

Gyre Therapeutics Announces Stock Offering Agreement

On May 22, 2025, Gyre Therapeutics, Inc. announced an underwriting agreement with Jefferies LLC to issue and sell 2,222,222 shares of common stock at $9.00 per share, with an option for underwriters to purchase an additional 333,333 shares. The company expects to raise approximately $18.5 million, which will be used to fund a Phase 2 clinical trial of F351 in the United States, as well as for research, development, and general corporate purposes. The offering is set to close on May 27, 2025, subject to customary conditions.

Gyre Therapeutics Achieves Key Milestone in Phase 3 Trial

On May 22, 2025, Gyre Therapeutics announced that its lead compound, Hydronidone, achieved the primary endpoint in a pivotal Phase 3 trial for treating liver fibrosis in patients with chronic hepatitis B in China. The 52-week trial demonstrated a statistically significant regression in liver fibrosis with Hydronidone compared to placebo, showing favorable safety and tolerability. This milestone positions Hydronidone as a potential first-in-class therapy for CHB-associated liver fibrosis, with plans for regulatory submission in China and further trials in the U.S.